Shafique Virani
Director/Board Member at TAUC3 Biologics Ltd.
Net worth: 1 M $ as of 29/04/2024
Shafique Virani active positions
Companies | Position | Start | End |
---|---|---|---|
TAUC3 Biologics Ltd.
TAUC3 Biologics Ltd. BiotechnologyHealth Technology TAUC3 Biologics Ltd. is engaged in the biotechnology industry. The company was founded on July19, 2019 and is headquartered in London, the United Kingdom. | Director/Board Member | - | - |
Career history of Shafique Virani
Former positions of Shafique Virani
Companies | Position | Start | End |
---|---|---|---|
RECURSION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 06/06/2022 | 31/05/2023 |
Corporate Officer/Principal | 31/05/2023 | 05/02/2024 | |
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Chief Executive Officer | 31/08/2017 | 30/11/2019 |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital. | Chief Executive Officer | 31/05/2018 | 30/11/2019 |
Biobridge LLC | Corporate Officer/Principal | 31/05/2017 | 30/11/2019 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 31/12/2003 | 31/05/2017 |
Training of Shafique Virani
The University of Nottingham | Doctorate Degree |
Statistics
International
United States | 6 |
United Kingdom | 3 |
Operational
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Director/Board Member | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
RECURSION PHARMACEUTICALS, INC. | Health Technology |
Private companies | 5 |
---|---|
TAUC3 Biologics Ltd.
TAUC3 Biologics Ltd. BiotechnologyHealth Technology TAUC3 Biologics Ltd. is engaged in the biotechnology industry. The company was founded on July19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Health Technology |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital. | Health Technology |
Biobridge LLC | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Shafique Virani
- Experience